Placebo Response in Studies of Major Depression: Variable, Substantial, and Growing
Walsh, B. Timothy
Seidman, Stuart N.
JAMA: The Journal of the American Medical Association 2002 April 10; 287(14): 1840-1847
CONTEXT: Intense debate persists about the need for placebo- controlled groups in clinical trials of medications for major depressive disorder (MDD). There is continuing interest in the development of new medications, but because effective antidepressants are already available, ethical concerns have been raised about the need for placebo groups in new trials. OBJECTIVE: To determine whether the characteristics of placebo control groups in antidepressant trials have changed over time. DATA SOURCES AND STUDY SELECTION: We searched MEDLINE and PsychLit for all controlled trials published in English between January 1981 and December 2000 in which adult outpatients with MDD were randomly assigned to receive medication or placebo. Seventy-five trials met our criteria for inclusion. DATA EXTRACTION: Data were extracted from the articles by 2 of the authors and discrepancies were resolved via discussion and additional review by a third author. DATA SYNTHESIS: The mean (SD) proportion of patients in the placebo group who responded was 29.7% (8.3%) (range, 12.5%-51.8%). Most studies examined more than a single active medication, and, in the active medication group with the greatest response, the mean (SD) proportion of patients responding was 50.1% (9.0%) (range, 31.6%-70.4%). Both the proportion of patients responding to placebo and the proportion responding to medication were significantly positively correlated with the year of publication (for placebo: n = 75; r = 0.45; 95% confidence interval [CI], 0.25-0.61; P
Showing items related by title, author, creator and subject.
A Renewed, Ethical Defense of Placebo-Controlled Trials of New Treatments for Major Depression and Anxiety Disorders Dunlop, Boadie W.; Banja, J. (2009-06)The use of placebo as a control condition in clinical trials of major depressive disorder and anxiety disorders continues to be an area of ethical concern. Typically, opponents of placebo controls argue that they violate ...
Placebo-Controlled Trials in Major Depression Are Necessary and Ethically Justifiable: How to Improve the Communication Between Researchers and Ethical Committees Adam, Dieter; Kasper, S.; Moller, H.J.; Singer, E.A. (2005-08)